M/s. Ranbaxy Farmaceutica Ltda : Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: M/s. Ranbaxy Farmaceutica Ltda : Pharmaceutical Import Records from India — 8 Products, $19.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. Ranbaxy Farmaceutica Ltda : — Pharmaceutical Importer Profile (2026) | 8 Products, $19.1M Trade | TransData Nexus

M/s. Ranbaxy Farmaceutica Ltda :

Pharmaceutical Importer · Brazil · CNS & Psychiatric Focus · $19.1M Total Trade · DGFT Verified

M/s. Ranbaxy Farmaceutica Ltda : is a pharmaceutical importer based in Brazil with a total trade value of $19.1M across 8 products in 5 therapeutic categories. Based on 433 verified import shipments from Indian Customs (DGFT) records, M/s. Ranbaxy Farmaceutica Ltda : is the #1 buyer in 1 product including Cefuroxime. M/s. Ranbaxy Farmaceutica Ltda : sources from 1 verified Indian supplier, with Sun Pharmaceutical Industries Limited accounting for 100.0% of imports.

M/s. Ranbaxy Farmaceutica Ltda : — Import Portfolio & Supplier Network

M/s. Ranbaxy Farmaceutica Ltda : import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/s. Ranbaxy Farmaceutica Ltda :?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$36.2M	1,162	100.0%

M/s. Ranbaxy Farmaceutica Ltda : sources from 1 verified Indian supplier across 677 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Nortriptyline hydrochloride capsules	$895.5K	22
Sertraline hcl TAB 50MG Pack:box100x10s	$804.5K	17
Clopidogrel bisulphate TAB 75MG	$570.6K	13
Amiodarone TAB 200MG 50x10s braz	$568.6K	13
Nortriptyline hydrochloride capsules	$535.3K	11
Citalopram TAB 20MG Pack:box30s	$500.0K	10
Sertraline hcl TAB 50MG Pack:box50x10s	$496.7K	16
Cinnarizine tablets 75MG Pack:box3x10s	$469.9K	10
Isotretinoin cap 20 MG Pack:box50x10s	$400.0K	8
Gliclazide TAB 60 MG 50x10b	$392.5K	8
Nortriptyline cap 50MG Pack:box3x10s	$388.6K	8
Clopidogrel bisulphate TAB 75MG	$379.9K	8
Oxcarbazepine tablets 300 MG Pack:box60s	$350.0K	7
Citalopram TAB 20MG Pack:box30s	$350.0K	7
Pregabalin capsules 75 MG Pack:4x7s	$329.2K	8

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cefuroxime	Advanced Antibiotics	$4.0M	81	2.7%	1
2	Citalopram	CNS & Psychiatric	$3.5M	71	1.4%	6
3	Amiodarone	Cardiovascular	$3.0M	59	4.0%	5
4	Gliclazide	Advanced Diabetes Medications	$2.4M	48	0.8%	8
5	Sertraline	CNS & Psychiatric	$2.4M	74	0.4%	18
6	Strip	Medical Devices & Diagnostics	$2.0M	64	1.0%	16
7	Clopidogrel	Cardiovascular	$1.7M	34	0.7%	18
8	Clonazepam	CNS & Psychiatric	$100.0K	2	0.1%	13

M/s. Ranbaxy Farmaceutica Ltda : imports 8 pharmaceutical products across 5 categories into Brazil totaling $19.1M. The company is the #1 buyer for 1 product: Cefuroxime.

M/s. Ranbaxy Farmaceutica Ltda : — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M/s. Ranbaxy Farmaceutica Ltda is a Brazilian pharmaceutical importer and wholesaler specializing in the distribution of finished pharmaceutical formulations. Established on November 4, 1993, the company is headquartered in Rio de Janeiro, Brazil. It operates under the legal entity CNPJ 73.663.650/0001-90, with a registered capital of R$ 17,366,900.00. (cnpj.ohub.com.br) The company is a subsidiary of Sun Pharma (Netherlands) B.V. and Ranbaxy Holdings UK Limited, both of which are foreign entities. (cnpj.ohub.com.br) Ranbaxy Farmaceutica Ltda plays a significant role in Brazil's pharmaceutical distribution network, serving as a key importer of generic medicines and contributing to the availability of affordable healthcare solutions across the country.

2Distribution Network

While specific details about M/s. Ranbaxy Farmaceutica Ltda's warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established distribution network within Brazil. The company has been involved in numerous shipments, primarily sourcing products from India, indicating a robust logistics framework capable of handling international trade efficiently. This network likely encompasses multiple distribution centers strategically located to ensure timely delivery of pharmaceutical products to various regions within Brazil.

3Industry Role

M/s. Ranbaxy Farmaceutica Ltda functions as a primary wholesaler in Brazil's pharmaceutical supply chain. By importing and distributing finished pharmaceutical formulations, the company bridges the gap between international manufacturers and the Brazilian market, ensuring the availability of essential medications. Its focus on generic medicines aligns with Brazil's healthcare objectives of providing cost-effective treatment options to the population. The company's operations are integral to the pharmaceutical distribution landscape, facilitating access to a wide range of therapeutic products.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/s. Ranbaxy Farmaceutica Ltda :

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

M/s. Ranbaxy Farmaceutica Ltda exhibits a high degree of sourcing concentration, with a total import value of $19.1 million USD from India over 433 shipments, primarily from a single supplier, Sun Pharmaceutical Industries Limited. This single-source dependency indicates a strategic choice to maintain a consistent supply chain and potentially leverage favorable terms with a key supplier. However, such concentration also poses risks, including vulnerability to supply disruptions or changes in supplier dynamics. The stability of this relationship is crucial for the company's operations, and any shifts in the supplier's capacity or policies could significantly impact M/s. Ranbaxy Farmaceutica Ltda's ability to meet market demand.

2Supply Chain Resilience

The resilience of M/s. Ranbaxy Farmaceutica Ltda's supply chain is closely tied to its reliance on a single supplier, Sun Pharmaceutical Industries Limited. This dependency may limit the company's ability to diversify its sourcing options, potentially exposing it to risks associated with supply chain disruptions. The company's focus on a limited number of therapeutic categories and formulations further concentrates its supply chain. To enhance resilience, M/s. Ranbaxy Farmaceutica Ltda could consider diversifying its supplier base and expanding its product portfolio, thereby mitigating potential risks associated with over-reliance on a single source.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the regulation of pharmaceutical products is overseen by the Brazilian Health Regulatory Agency, known as Anvisa (Agência Nacional de Vigilância Sanitária). Anvisa is responsible for the authorization of clinical trials, market authorization of drugs and biological products, and post-marketing surveillance. (gov.br) The agency classifies drugs into various categories, including new synthetic and semi-synthetic drugs, generic drugs, similar drugs (branded generics), and others, each subject to specific regulatory requirements. For Indian pharmaceutical exporters, understanding Anvisa's regulatory framework is essential for ensuring compliance and facilitating the market entry of their products into Brazil.

2Import Licensing & GMP

Import licensing in Brazil is governed by Anvisa, which requires pre-market approval ("registro") for pharmaceutical products considered to present the greatest health risks. This approval process ensures that imported drugs meet Brazilian sanitary regulations before commercialization. (gov.br) Good Manufacturing Practice (GMP) certification is also mandatory for pharmaceutical products imported into Brazil. Anvisa recognizes GMP certifications from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the acceptance of international standards. Indian exporters should ensure that their manufacturing facilities hold valid GMP certifications recognized by Anvisa to comply with Brazilian import requirements.

M/s. Ranbaxy Farmaceutica Ltda : — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

M/s. Ranbaxy Farmaceutica Ltda's focus on importing finished pharmaceutical formulations in the therapeutic categories of Central Nervous System (CNS) & Psychiatric, Cardiovascular, and Advanced Antibiotics indicates a strategic alignment with prevalent health concerns in Brazil. The significant import values in these categories suggest a strong market demand for treatments in these areas. By concentrating on these therapeutic segments, the company aims to address critical healthcare needs and capitalize on the substantial market opportunities they present.

2Sourcing Profile

M/s. Ranbaxy Farmaceutica Ltda's sourcing strategy is centered on importing generic drug formulations from India, with a particular emphasis on specific therapeutic categories. The company's preference for finished pharmaceutical formulations over raw Active Pharmaceutical Ingredients (APIs) indicates a focus on ready-to-market products that can be distributed efficiently within Brazil. This approach leverages India's established pharmaceutical manufacturing capabilities and cost advantages, aligning with the company's objective to provide affordable healthcare solutions to the Brazilian market.

3Market Positioning

Seller's Guide — How to Become a Supplier to M/s. Ranbaxy Farmaceutica Ltda :

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with M/s. Ranbaxy Farmaceutica Ltda, particularly in the therapeutic categories where the company has a significant import presence. By offering complementary products or expanding the existing product portfolio, Indian exporters can strengthen their partnership with the company. Additionally, addressing any gaps in the company's current sourcing strategy, such as diversifying the supplier base or introducing innovative formulations, could enhance the resilience and competitiveness of M/s. Ranbaxy Farmaceutica Ltda's supply chain.

2Requirements & Qualifications

Indian exporters aiming to supply M/s. Ranbaxy Farmaceutica Ltda and the broader Brazilian market must ensure compliance with Anvisa's regulatory requirements. This includes obtaining pre-market approval for pharmaceutical products, holding GMP certifications recognized by Anvisa, and adhering to labeling and packaging standards. Additionally, maintaining a robust quality assurance system and staying informed about regulatory updates are essential to meet the expectations of Brazilian importers and regulatory authorities.

3How to Approach

Frequently Asked Questions — M/s. Ranbaxy Farmaceutica Ltda :

What products does M/s. Ranbaxy Farmaceutica Ltda : import from India?

M/s. Ranbaxy Farmaceutica Ltda : imports 8 pharmaceutical products across 5 categories. Top imports: Cefuroxime ($4.0M), Citalopram ($3.5M), Amiodarone ($3.0M), Gliclazide ($2.4M), Sertraline ($2.4M).

Who supplies pharmaceuticals to M/s. Ranbaxy Farmaceutica Ltda : from India?

M/s. Ranbaxy Farmaceutica Ltda : sources from 1 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (100.0% of imports, $36.2M).

What is M/s. Ranbaxy Farmaceutica Ltda :'s total pharmaceutical import value?

M/s. Ranbaxy Farmaceutica Ltda :'s total pharmaceutical import value from India is $19.1M, based on 433 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/s. Ranbaxy Farmaceutica Ltda : focus on?

M/s. Ranbaxy Farmaceutica Ltda : imports across 5 categories. The largest: CNS & Psychiatric (31.4%), Cardiovascular (24.3%), Advanced Antibiotics (21.2%).

Get Full M/s. Ranbaxy Farmaceutica Ltda : Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.